Previous close | 11.96 |
Open | 11.83 |
Bid | 12.14 x 100 |
Ask | 12.19 x 100 |
Day's range | 11.70 - 12.28 |
52-week range | 5.71 - 16.99 |
Volume | |
Avg. volume | 813,327 |
Market cap | 943.568M |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MORRISVILLE, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024. The company will host a webcast at 8:30 a.m. ET on May 14, 2024 to discuss the financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia’s chief executive officer, said: “We continue to vigorously pursue final agency action for YUTREPIA’s approval for pulmonary arterial hypertension (PAH) and pulmonary hypertension
MORRISVILLE, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the company will present data related to the investigational use of L606 (liposomal treprostinil) inhalation suspension in people with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, California. Rajeev Saggar, MD,
MORRISVILLE, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Michael Kaseta, chief operating officer and chief financial officer, will provide an update on the company's business during a fireside chat at the BofA Securities Health Care Conference 2024 on Tuesday, May 14, 2024, beginning at 5:00 p.m. PT in Las Vegas, Nevada. Access to a webcast will be available to investors and other interested parties by accessing Liquidia’s website at https://li